Tracy Beth Høeg, MD, PhD, is the interim director of the FDA's Center for Drug Evaluation and Research (CDER).[1][4] In this role, she reported an interest in investigating the safety of SSRI antidepressants during pregnancy and RSV antibodies in infants.[1] SSRIs are commonly used as the first line of treatment for depression, anxiety disorders, and other mental illnesses.[1] In July 2025, an FDA expert panel led by Høeg and Makary listed the risks of SSRIs in pregnancy, including potential birth defects.[1] The American Psychiatric Association and the American College of Obstetricians and Gynecologists criticized this panel and emphasized the importance of SSRIs in the treatment of mental health problems in pregnant women.[1] Untreated depression during pregnancy can lead to risks such as premature birth, preeclampsia, low birth weight or suicide.[1] Høeg emphasized the need for more randomized trials in pregnant women in the field of women's health.[1] In addition to SSRIs, he plans to explore monoclonal antibodies such as Beyfortus and Enflonsia against RSV.[1]